Is Cyclerion Therapeutics Stock a Good Investment?
Cyclerion Therapeutics Investment Advice | CYCN |
- Examine Cyclerion Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cyclerion Therapeutics' leadership team and their track record. Good management can help Cyclerion Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cyclerion Therapeutics' business and its evolving consumer preferences.
- Compare Cyclerion Therapeutics' performance and market position to its competitors. Analyze how Cyclerion Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Cyclerion Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cyclerion Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cyclerion Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cyclerion Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Cyclerion Therapeutics Stock
Researching Cyclerion Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.71. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cyclerion Therapeutics recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 16th of May 2023.
To determine if Cyclerion Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cyclerion Therapeutics' research are outlined below:
| Cyclerion Therapeutics had very high historical volatility over the last 90 days | |
| Cyclerion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5.26 M) with loss before overhead, payroll, taxes, and interest of (29.75 M). | |
| Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
| Cyclerion Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 568 shares by Cheryl Gault of Cyclerion Therapeutics at 19.04 subject to Rule 16b-3 |
Cyclerion Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Cyclerion Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cyclerion Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cyclerion Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Cyclerion Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cyclerion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cyclerion Therapeutics backward and forwards among themselves. Cyclerion Therapeutics' institutional investor refers to the entity that pools money to purchase Cyclerion Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 K | Group One Trading, Lp | 2024-06-30 | 540 | Royal Bank Of Canada | 2024-06-30 | 416 | Activest Wealth Management | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 16.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Farmers National Bank | 2024-06-30 | 0.0 | Pnc Financial Services Group Inc | 2024-09-30 | 0.0 | Slate Path Capital Lp | 2024-09-30 | 357.9 K | Mfn Partners Management, Lp | 2024-06-30 | 169.5 K |
Cyclerion Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.85 M.Market Cap |
|
Cyclerion Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.57) | (1.65) | |
| Return On Capital Employed | (0.85) | (0.81) | |
| Return On Assets | (1.57) | (1.65) | |
| Return On Equity | (1.86) | (1.77) |
Determining Cyclerion Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Cyclerion Therapeutics is a good buy. For example, gross profit margin measures Cyclerion Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cyclerion Therapeutics' profitability and make more informed investment decisions.
Evaluate Cyclerion Therapeutics' management efficiency
Cyclerion Therapeutics has return on total asset (ROA) of (0.4655) % which means that it has lost $0.4655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5025) %, meaning that it created substantial loss on money invested by shareholders. Cyclerion Therapeutics' management efficiency ratios could be used to measure how well Cyclerion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -1.65. In addition to that, Return On Capital Employed is likely to grow to -0.81. At this time, Cyclerion Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 29th of November 2024, Asset Turnover is likely to grow to 0.02, while Total Assets are likely to drop about 12.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.83 | 4.59 | |
| Tangible Book Value Per Share | 4.83 | 4.59 | |
| Enterprise Value Over EBITDA | (0.02) | (0.02) | |
| Price Book Value Ratio | 0.69 | 0.73 | |
| Enterprise Value Multiple | (0.02) | (0.02) | |
| Price Fair Value | 0.69 | 0.73 |
Cyclerion Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.924 |
Basic technical analysis of Cyclerion Stock
As of the 29th of November, Cyclerion Therapeutics shows the mean deviation of 7.07, and Risk Adjusted Performance of 0.0288. Cyclerion Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cyclerion Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclerion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclerion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclerion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyclerion Therapeutics' Outstanding Corporate Bonds
Cyclerion Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cyclerion Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cyclerion bonds can be classified according to their maturity, which is the date when Cyclerion Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Cyclerion Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cyclerion Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0288 | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 7.07 | |||
| Semi Deviation | 9.09 | |||
| Downside Deviation | 9.37 | |||
| Coefficient Of Variation | 3944.61 | |||
| Standard Deviation | 12.42 | |||
| Variance | 154.3 | |||
| Information Ratio | 0.0153 | |||
| Jensen Alpha | 0.4351 | |||
| Total Risk Alpha | (1.57) | |||
| Sortino Ratio | 0.0202 | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 77.82 | |||
| Value At Risk | (15.79) | |||
| Potential Upside | 18.75 | |||
| Downside Variance | 87.76 | |||
| Semi Variance | 82.56 | |||
| Expected Short fall | (8.36) | |||
| Skewness | 2.09 | |||
| Kurtosis | 9.68 |
| Risk Adjusted Performance | 0.0288 | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 7.07 | |||
| Semi Deviation | 9.09 | |||
| Downside Deviation | 9.37 | |||
| Coefficient Of Variation | 3944.61 | |||
| Standard Deviation | 12.42 | |||
| Variance | 154.3 | |||
| Information Ratio | 0.0153 | |||
| Jensen Alpha | 0.4351 | |||
| Total Risk Alpha | (1.57) | |||
| Sortino Ratio | 0.0202 | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 77.82 | |||
| Value At Risk | (15.79) | |||
| Potential Upside | 18.75 | |||
| Downside Variance | 87.76 | |||
| Semi Variance | 82.56 | |||
| Expected Short fall | (8.36) | |||
| Skewness | 2.09 | |||
| Kurtosis | 9.68 |
Consider Cyclerion Therapeutics' intraday indicators
Cyclerion Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cyclerion Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 126838.0 | |||
| Daily Balance Of Power | 0.1333 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 2.18 | |||
| Day Typical Price | 2.19 | |||
| Price Action Indicator | 0.04 | |||
| Period Momentum Indicator | 0.04 |
Cyclerion Therapeutics Corporate Filings
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 12th of July 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 14th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Cyclerion Stock media impact
Far too much social signal, news, headlines, and media speculation about Cyclerion Therapeutics that are available to investors today. That information is available publicly through Cyclerion media outlets and privately through word of mouth or via Cyclerion internal channels. However, regardless of the origin, that massive amount of Cyclerion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cyclerion Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cyclerion Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cyclerion Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cyclerion Therapeutics alpha.
Cyclerion Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cyclerion Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cyclerion Therapeutics Corporate Management
| Todd Milne | Senior Innovation | Profile | |
| Cheryl Gault | Chief Officer | Profile | |
| Jessica Rennekamp | Associate Communications | Profile | |
| Rhonda CPA | Chief Officer | Profile | |
| Christopher Winrow | Sr Lead | Profile | |
| Jennifer Chickering | Director Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Cyclerion Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.